Adamas Pharmaceuticals Inc., primed by a recent $25 million milestone payment on an unrelated program, is starting a pivotal phase III study to test the ability of ADS-5102, its experimental extended-release formulation of generic drug amantadine, to quell involuntary movements tied to Parkinson's disease (PD) treatment.